HIV relapse dashes hopes for Boston researchers; GSK, Theravance post positive PhIII asthma data;

@FierceBiotech: Chutes & Ladders this week: GoBalto gets new CEO as founder Chung steps down & more. Feature | Follow @FierceBiotech

@JohnCFierce: Mixed outcome for lifitegrast PhIII, 1 of Fleming Ornskov's 1st deals for Shire-$160M SARcode buyout - hit 1 missed. Release | Follow @JohnCFierce

@DamianFierce: So Geron is soaring on these imetelstat results "embargoed" for Monday. More | Follow @DamianFierce

@EmilyMFierce: With drug-resistant malaria strains on the rise, a new report says basic research for malaria needs a boost. Story | Follow @EmilyMFierce

> Signs of HIV have returned in two bone marrow transplant patients who became virus-free over the summer, a setback for researchers who had hoped their discovery would lead to a cure. Story

> Novartis ($NVS) leads the pack among drug developers targeting sporadic inclusion body myositis, a rare muscle-wasting disease with no approved therapies. Article

> GlaxoSmithKline ($GSK) and partner Theravance ($THRX) posted promising Phase III results for Breo Ellipta in asthma patients. The drug is already approved to treat COPD. Release

> AstraZeneca ($AZN) is the first drugmaker to win European approval for an inhaled, four-in-one flu vaccine for children. More

Medical Device News

@FierceMedDev: Biocartis and VIB join forces to develop unique diagnostic cancer test. Release | Follow @FierceMedDev

@MarkHFierce: An Xconomy contributor offers another point-of-vew on the 23andMe issue - a clash of cultures and business models. More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: 'Worm-shaped' nanoparticles best at infiltrating breast cancer. Story from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: China finally allows the FDA to add inspectors to bolster oversight. More | Follow @GalenMoore

> Jarvik Heart's Japan regulatory win gives Thoratec a new heart pump challenge. Story

> Thermo's 'ever-increasing appetite for debt' raises analysts' eyebrows. Article

> 23andMe capitulates, yanking all health-related gene tests pending FDA review. Report

> Medtronic's spinal division generates a shot of good news. More

> Sorin collects EU approval for its Intensia family of cardiac devices. Item

Pharma News

@FiercePharma: Whooping cough is making a comeback--and the FDA thinks it might know why. Story from FierceVaccines | Follow @FiercePharma

@EricPFierce: Mylan intends to launch 800 injectable products in next 5 years, 150 in US, now that it own Agila. Yesterday's story | Follow @EricPFierce

@CarlyHFierce: NICE smiles on Sanofi's Aubagio the day after snubbing Lemtrada. Story | Follow @CarlyHFierce

> Feds seize documents from Reckitt Benckiser pharma. Story

> Actavis' former CEO is betting on biosimilars. Article

> AstraZeneca is first to win EU approval for an inhaled 4-in-1 flu vaccine. More

Suggested Articles

The ambitious target is enabled by an AI discovery platform that Healx thinks gives it a scalability that has more in common with tech than biotech.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.